Latest news with #MDRF
Time of India
26-05-2025
- Health
- Time of India
MDRF and Russia's Almazov Centre Partner for diabetes research
Chennai: The Madras Diabetes Research Foundation ( MDRF ) has signed a research collaboration with the Almazov National Medical Research Centre , based in Saint Petersburg, Russia. The partnership will focus on developing new diagnostics and treatment strategies for diabetes, with an emphasis on Gestational Diabetes Mellitus (GDM). It will also explore emerging areas such as artificial intelligence and precision medicine in diabetes care. The memorandum of understanding (MoU) was signed by Dr. V. Mohan of MDRF and Prof. Evgeny Shlyakhto, Director General of the Almazov Centre. The agreement includes training and exchange programs for medical specialists, joint conferences, academic meetings, collaborative publications, and educational and cultural exchanges. Joint research projects on gestational diabetes have begun, involving Dr. Polina V. Popova and her team from Almazov's Endocrinology Department and Dr. Mohan's team at MDRF. The collaboration is expected to expand further in the coming months.
Hindustan Times
26-05-2025
- Health
- Hindustan Times
Pistachios are more than just a snack, experts weigh in
They've long been sprinkled over biryanis, tucked into mithai, and enjoyed during festive feasts — but pistachios are finally being recognised for more than just their garnish-worthy appeal. As India grapples with soaring numbers of diabetes and prediabetes — 101 million and 136 million adults, respectively — this humble nut is quietly being recast as a nutritional powerhouse. Earlier this year, the Madras Diabetes Research Foundation (MDRF) published a study in The Journal of Nutrition that underscores pistachios' potential in diabetes prevention. Led by MDRF chairman Dr V Mohan, the 12-week clinical trial involving 120 individuals with prediabetes found that consuming 30 grams of roasted pistachios before breakfast and dinner led to measurable improvements, from better blood sugar control to reductions in weight, triglyceride levels and waist circumference. 'It's a simple, effective intervention,' says Dr Mohan. Nutritionally, pistachios tick multiple boxes. 'They're rich in protein for muscle health, packed with dietary fibre to aid digestion and regulate blood sugar, and full of heart-friendly fats,' says nutritionist Dr Anjana Kalia, adding, 'Roasted and unsalted varieties make for one of the best on-the-go snacks.' Their benefits extend further: folate for expectant mothers, magnesium for ageing bones, and heart-healthy fats for just about everyone. 'Pistachios are especially good for pregnant women due to their folate content, and for elders because of their bone-strengthening properties,' adds Dr Drishya Ale, a dietitian at Paras Health, Gurugram. It's no surprise, then, that pistachios are becoming more than just festive fare. 'There's been a post-pandemic shift in how India snacks,' notes Sumit Saran, India representative of American Pistachio Growers, adding, 'Earlier, pistachios were mainly used as a garnish. Now, people are embracing them as part of their everyday diet.' Though India doesn't commercially grow pistachios, California-grown varieties are widely available. 'You'll find them in stores across the country,' Saran adds and says, 'All consumers need to do is look for California pistachios and pick their preferred brand.' Pistachios, it seems, are no longer just a treat. They're a habit worth developing.
The Hindu
23-05-2025
- Health
- The Hindu
Madras Diabetes Research Foundation and Russia's Almazov Centre sign MoU for diabetes research
The Madras Diabetes Research Foundation (MDRF) has signed a memorandum of understanding with the Almazov National Medical Research Centre in Saint Petersburg, Russia, to advance collaborative research in diabetes care. A press release said the partnership would focus on developing new diagnostic and treatment strategies, particularly for gestational diabetes mellitus. It will also explore emerging areas such as artificial intelligence (AI) and precision medicine in diabetes management. The MoU was signed by V. Mohan, Chairman, MDRF, and Evgeny Shlyakhto, Director-General of the Almazov Centre. The agreement includes joint research projects, academic exchanges, collaborative publications, and training programmes. Dr. Mohan said: 'This collaboration reflects our shared commitment to tackling diabetes through scientific innovation and global cooperation. AI and precision medicine offer exciting possibilities to improve care.' Dr. Mohan also delivered a keynote on AI in diabetes at the 8th Saint Petersburg Medical Innovation Forum, held at the Almazov Centre. Joint research on gestational diabetes is already under way, with teams led by Polina V. Popova from Almazov and MDRF researchers, the press release added.
The Print
08-05-2025
- Health
- The Print
New subtype of diabetes found in India could change how rare forms of disease are treated
These patients with diabetes, now identified as those with Maturity-Onset Diabetes of the Young (MODY) 15, were subjected to extensive genetic testing due to their atypical biomarkers—measurable indicators that reflect a certain disease. The discovery by scientists associated with the Madras Diabetes Research Foundation (MDRF), an Indian Council of Medical Research (ICMR) Centre of Excellence, in collaboration with Washington University in Missouri, US, is based on the identification of a new diabetes subtype in 20 patients in India. New Delhi: Scientists from India, along with their counterparts in the US, have discovered a new subtype of the disease in Indian patients, marking a landmark achievement in diabetes research and potentially transforming how certain rare forms of the disease are diagnosed and treated worldwide. MODY is a rare and genetic form of diabetes, distinct from commoner forms of the disease such as type 1 and type 2 diabetes. It is caused by mutations in a single gene, typically present in adolescents and young adults. MODY is estimated to affect nearly 2-3 percent of all people with diabetes. While 14 MODY subtypes have been recognised so far, this newly identified variant—named MODY 15—upends long-standing assumptions about how the disease develops. The discovery has been published in the journal Diabetes two weeks ago. 'We are excited that we have discovered a new subtype of MODY diabetes. This work underscores the importance of genetic testing and functional understanding for precision diagnosis of diabetes in general and MODY subtypes of diabetes in particular,' Dr V. Mohan, MDRF chairman and a researcher associated with the discovery, said in a press briefing Thursday. By identifying these unique subtypes of MODY, clinicians can get closer to providing more precise diagnosis, treatment and better care for individuals. Also Read: Pune-based firm receives major international grant to accelerate development of Nipah virus vaccine How new subtype is distinct Diabetes, also known as diabetes mellitus, is actually a group of common endocrine disorders, mainly characterised by sustained high blood sugar levels due to absent or low insulin levels. The main symptoms of disease—seen in almost all forms—include excessive thirst, hunger and urination, weight loss, fatigue and blurred vision, and, if left untreated, complications such as disorders of kidney, cardiovascular system, nerves and eyes. While type 1 diabetes is characterised by complete loss of the insulin-producing beta cells due to autoimmune or idiopathic (unknown) reasons, type 2 diabetes is mainly triggered by insulin resistance or the body's inability to respond to insulin, often combined with relatively reduced insulin secretion. MODY, on the other hand, is triggered due to one of several single-gene mutations causing defects in insulin production. Colin G. Nichols, the lead researcher of this work from Washington University's School of Medicine, explained that MODY 15 is caused by an affected ABCC8 gene that controls the functioning of insulin-producing β cells in the pancreas. Usually, ABCC8 mutations work through Gain Of Function (GOF) mutations, which lead to enhanced ABCC8 protein activity, and this can occur in the neonatal period when it is known as neonatal diabetes, he explained in a statement. In adults, it occurs as ABCC8 MODY or MODY 12, Nicholas said, adding that through his lab's collaborative work with MDRF, using various experiments in the laboratory, researchers were able to show some novel mutations in the Indian patients with MODY, which occur as Loss Of Function (LOF). 'LOF mutations abolish or reduce the activity of protein, and they normally lead to Congenital Hyperinsulinism (CHI), which presents as persistent low blood glucose levels (hypoglycemia) in childhood. These patients seem to have had CHI earlier but crossed over to the opposite condition, of high blood sugar (diabetes) in later life,' he said, adding, 'This is the first demonstration of this mechanism in a MODY subtype to our knowledge.' Radha Venkatesan, executive scientific officer, head of molecular genetics, and the lead researcher from MDRF, said that the discovery of the novel genetic subtype of MODY represents a significant advancement in understanding this type of diabetes and explains the function of potassium ATP (K-ATP) channels in the pancreatic beta cell membrane. K-ATP channels are a kind of molecular switch which determines whether or not insulin is released. 'Through our work in the lab and follow-up of our patients, we propose that diabetes driven by KATP-Gain of Function and KATP-Loss Of Function mutations should be officially recognised as distinct disease subtypes, with different molecular basis and different clinical and therapeutic implications,' Venkatesan said. Implications on treatment for rare forms of diabetes Type 1 diabetes is mainly treated with insulin replacement therapy. On the other hand, type 2 diabetes, in nearly 90 percent of cases, is managed by anti-diabetic medicines and lifestyle modification, even though nearly 10 percent of patients with this condition tend to need insulin. Some forms of MODY can be treated with anti-diabetic medicine, while others need insulin, and a few do not need any long-term treatment at all. Talking to ThePrint, Mohan explained that genetic testing to identify the subtype of diabetes is carried out in atypical cases, when doctors are not sure whether somebody has type 1 or type 2 diabetes. 'We have got certain criteria to do genetic testing for. For example, all children below 6 months of age have to undergo genetic testing,' he said. 'Secondly, if we feel that somebody has type 1 diabetes clinically, but all the markers for type 1 diabetes, like GAD (glutamic acid decarboxylase, associated with type 1 antibodies), antibodies are negative, and there is a family history of diabetes this suggests that it may not be type 1 diabetes.' Similarly, said the clinician-scientist, if one is treating a patient as type 2 diabetes but if the patient is lean, does not have obesity, and other markers of insulin resistance—such as the thickening of the skin of the neck or 'acanthosis nigricans'—which are all classical features of type 2 diabetes, then doctors need to probe whether this could this be some other form of diabetes and, in such individuals, genetic testing can be planned. Regarding the treatment, if it is a Gain of Function (GOF) ABCC8 mutation, like neonatal diabetes, MODY 12, MODY 1 or MODY 3, then sulphonylurea—a common medication for type 2 diabetes—is the treatment of choice, Mohan explained. 'In the case of MODY 15 patients, sulphonylurea treatment did not work in any of these patients and they were managed with different drugs,' he said. But since they were a series of patients who came from different centres and were referred to MDRF mainly for the genetic testing, the researchers are still not clear which drug would be best. 'We will have to collect the largest series of patients and do a randomised clinical trial to see which drug would suit these patients best,' Mohan added. The discovery not only expands the scientific understanding of MODY, researchers have maintained, but also underscores the urgent need for wider access to genetic screening, particularly in countries like India, where such testing is not yet part of routine diabetes care. This breakthrough could mark a turning point in advancing personalised diagnosis, treatment, and long-term management for thousands of individuals living with undetected or misclassified forms of diabetes, they said. (Edited by Sanya Mathur) Also Read: Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO
The Hindu
08-05-2025
- Health
- The Hindu
MDRF, U.S. researchers call for precision treatment following discovery of a new subtype of monogenic diabetes
Scientists from the Madras Diabetes Research Foundation (MDRF), Chennai, in collaboration with Washington University School of Medicine in St. Louis, United States, have discovered a previously unrecognised subtype of Maturity-Onset Diabetes of the Young (MODY), and have called for wider access to genetic screening and precision treatment for diabetes patients, particularly in India. The findings were presented to the media at a conference held at the MDRF here on Thursday. MODY is a rare, inherited form of diabetes caused by mutations in a single gene, typically appearing in adolescents and young adults. While 13 MODY subtypes have been recognised to date, the newly identified variant challenges long-standing assumptions about the condition, doctors said. Need for genetic testing in diabetes management Researchers say the breakthrough not only adds to scientific understanding but also underscores the urgent need to integrate genetic testing into routine diabetes care. This, they noted, could mark a turning point in improving diagnosis, treatment, and long-term disease management for thousands of individuals living with undetected or misclassified forms of monogenic diabetes. The study, published in the journal — Diabetes —of the American Diabetes Association, identifies Loss of Function (LOF) mutations in the ABCC8 gene (it helps regulate insulin release in the pancreas by controlling a channel that responds to glucose levels, allowing insulin to be released into the bloodstream, when needed), in contrast to the Gain of Function (GOF) mutations previously linked to MODY and neonatal diabetes. The new variant results in early-life hypoglycemia, followed by later-onset diabetes — a progression previously undocumented in MODY cases. Colin G. Nichols, lead researcher, Washington University School of Medicine, highlighted in the study that the LOF mutation impairs potassium channel function in pancreatic beta cells, disrupting insulin secretion. He said the study marked the first observed switch from congenital hyperinsulinism to diabetes in maturity-onset diabetes of the young context. Clinical implications and treatment possibilities Radha Venkatesan, executive scientific officer, head of molecular genomics at MDRF and co-lead author, emphasised the clinical implications of this discovery. 'This variant does not respond to conventional treatments such as sulphonylureas, which are effective in other MODY forms. Understanding the underlying genetic mechanism is key to guiding appropriate therapy,' she said. V. Mohan, chairman of MDRF, reiterated the importance of incorporating genetic testing into standard diabetes diagnosis. 'Many patients with MODY remain undiagnosed or misclassified as having type 1 or type 2 diabetes. This discovery strengthens the case for precision diagnosis and treatment,' he said. The findings are based on clinical data and laboratory analysis of Indian patients. Researchers believe that expanding access to genetic testing could lead to earlier detection and more effective care for individuals with monogenic forms of diabetes.
